Tirzepatide represents a significant advancement in metabolic medicine. Unlike earlier weight loss medications that targeted a single hormonal pathway, tirzepatide is a dual agonist — it activates both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This dual mechanism produces weight loss outcomes that have consistently outperformed any single-agent therapy in the clinical literature.
How Tirzepatide Works
GLP-1 and GIP are incretin hormones — signaling molecules released by the gut in response to food. They communicate with the brain's appetite centers, slow gastric emptying (the rate at which food leaves the stomach), and regulate insulin secretion. By activating both receptors, tirzepatide produces a more powerful and sustained reduction in appetite than GLP-1 agonists alone, while also improving insulin sensitivity and metabolic efficiency.
The result is a significant reduction in caloric intake driven not by willpower, but by a fundamental shift in how the body processes hunger signals.
What the Clinical Trials Show
The SURPASS clinical trial program — five large-scale trials in patients with type 2 diabetes — demonstrated that tirzepatide at doses of 5–15 mg per week reduced body weight by 5.4 to 11.7 kg. A "sizable proportion of patients (20.7% to 68.4%) lost more than 10% of their baseline body weight," and tirzepatide was more effective in reducing body weight than semaglutide across head-to-head comparisons.[1]
A 2025 systematic review and network meta-analysis in Expert Opinion on Drug Safety confirmed dose-dependent weight reductions, with patients receiving the 15 mg dose losing an average of 14.5 kg. The analysis found that tirzepatide "significantly increased the likelihood of achieving ≥15% weight loss" compared to other agents.[2]
Beyond weight reduction, tirzepatide has demonstrated meaningful improvements in obesity-related complications. A 2024 study found that tirzepatide enables many individuals to achieve ≥20% weight loss and improves conditions such as sleep apnea and heart failure — outcomes that extend well beyond the scale.[3]
What to Expect at Nectar Wellness
Our tirzepatide program is compounded and prescribed under the supervision of our clinical team. Treatment begins with a comprehensive consultation to assess your health history, metabolic goals, and baseline labs. Dosing is titrated gradually — starting low and increasing over several weeks — to allow your body to adjust and minimize any gastrointestinal side effects during the early phase.
Most clients begin noticing meaningful appetite reduction within the first 2–4 weeks. Significant weight changes typically become apparent by weeks 8–12, with continued progress through the duration of the program. Our nurses are available throughout your treatment for ongoing support, dose adjustments, and monitoring.
"Five clinical trials have shown that tirzepatide at 5–15 mg per week reduces both HbA1c and body weight by amounts unprecedented for a single agent." — Nauck & D'Alessio, Cardiovascular Diabetology, 2022